The objective of the present study was to develop an immediate release tablet of Dasatinib using different concentrations of cross carmelose sodium (CCS) as superdisintegrant with a view to gain rapid disintegration in gastric pH for treatment of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML).Five different formulations of Dasatinib immediate release tablets were prepared using wet granulation method. Different pre compression and post compression characterization of tablet was carried out. In vitro drug release studies were carried out in USP II paddle type dissolution apparatus for different formulation and the batch containing 5% CCS gave maximum amount of drug release of 99.14%.Drug and excipients compatibility studies were carried out through FTIR spectroscopy. FTIR spectroscopy studies reveled that there is no interaction between drug and different excipients used in formulation. Short term stability studies (at 40±2oC/75±5% RH) on the best formulation indicated that there no significant changes in drug content.